An interventional study of Placebo and MPRO3 in Colon Neoplasms, sponsored by hy Co., LTD.. Recruiting at 1 site in South Korea. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by hy Co., LTD. · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Colonic Neoplasms with a site in Korea, Republic of — 13 open to participants now, 29 under way, 10 of them phase 3. Colonic Neoplasms · Korea, Republic of.
Among the 82 studies in Colonic Neoplasms with a site in Korea, Republic of, this one is the 44th largest by planned enrollment of the 65 interventional ones that give a count, is one of 2 that started in 2026, is one of 23 with no phase, reaches primary completion later than 21 of the 28 other live ones, and was the 82nd registered.
2,457 studies on the registry are indexed under Colonic Neoplasms; 458 are open to participants now.
Browse Colonic Neoplasms studies →13 of the 82 studies in Colonic Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Incyte Corporation · Sites in Korea, Republic of, United States, Argentina and 19 more countries
Ages 18+
Pheon Therapeutics · Sites in Korea, Republic of, United States, Spain
Ages 18+
Merck Sharp & Dohme LLC · Sites in Korea, Republic of, United States, Argentina and 26 more countries
Ages 18+
Ulsan University Hospital · Sites in Korea, Republic of
Ages 19+
Yonsei University · Sites in Korea, Republic of
Ages 19–80
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 328 Colonic Neoplasms studies recruiting now, 204 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 22 · Phase 3 14 · Phase 4 2
First in 1991; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 75 across 1,711 interventional studies indexed under Colonic Neoplasms.
Median enrollment 174 across the 65 interventional studies, 300 across the 15 observational. Of the 36 that completed or were terminated, 9 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 82 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with hy Co., LTD. as lead sponsor.
hy Co., LTD. has 1 study filed under Colonic Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies in Colonic Neoplasms with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04416490Boryung Pharmaceutical Co., LtdOxaliplatin Adjuvant Chemotherapy After Curative Resection of Primary Colon Cancer | 2027-02 |
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
| NCT07127874Pheon TherapeuticsA Study of PHN-012 in Patients With Advanced Solid Tumors | 2027-09 |
| NCT05544929Novartis PharmaceuticalsA Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | 2027-10-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 82 studies in Colonic Neoplasms with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the effects of MPRO3(probiotics mixture) supplementation on surgical outcomes and gut health in patients undergoing surgery for colon cancer.The main question is whether MPRO3 supplementation before and after surgery can reduce postoperative infectious complications compared with placebo.Participants will take either MPRO3 or a placebo once daily for 13 weeks, from 1 week before surgery to 12 weeks after surgery. Researchers will compare the two groups to assess postoperative infectious complications, other clinical outcomes, and changes in the gut microbiome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo is a matching formulation that does not contain the three probiotic strains included in MPR03.
Dietary Supplement: Placebo
MPR03 is a probiotic formulation containing a mixture of three probiotic strains: Bifidobacterium animalis subsp. lactis HY8002, Lacticaseibacillus paracasei HY2782, and Lactiplantibacillus plantarum HY7712.
Dietary Supplement: MPRO3
Participants will receive one placebo capsule orally once daily after breakfast for 13 weeks.
Participants will receive one MPRO3 capsule orally once daily after breakfast for 13 weeks.
Postoperative Infectious Complications (Infectious complications)
The occurrence of postoperative infectious complications is assessed according to the CDC/NHSN criteria.
Time frame: 4 weeks after surgery, 12 weeks after surgery
Comprehensive Complication Index
Postoperative complications are graded according to the Clavien-Dindo classification and summarized as a Comprehensive Complication Index score ranging from 0 to 100.
Time frame: 4 weeks after surgery, 12 weeks after surgery
Postoperative Length of Hospital Stay (LOS)
Postoperative length of hospital stay is calculated from the date of surgery to hospital discharge based on medical records.
Time frame: 4 weeks after surgery
Inflammation-related Marker 1: Glasgow prognostic score (GPS)
The Glasgow Prognostic Score (GPS) is assessed using inflammatory markers measured in venous blood and is calculated based on serum albumin and high-sensitivity C-reactive protein (HS-CRP) levels. The total score ranges from 0 to 2. A score of 0 is assigned when HS-CRP is ≤10 mg/L and albumin is ≥35 g/L. A score of 1 is assigned when either HS-CRP is \>10 mg/L or albumin is \<35 g/L. A score of 2 is assigned when HS-CRP is \>10 mg/L and albumin is \<35 g/L. Higher scores indicate a worse prognostic status.
Time frame: Baseline, 4 weeks after surgery, 12 weeks after surgery
Inflammation-related Markers 2: White Blood Cell (WBC), C-reactive protein (CRP), Neutrophils, lymphocytes, Monocytes, Platelets (PLT), neutrophil-to-lymphocyte ratio (NLR)
Inflammation-related markers are assessed using venous blood samples. WBC and Platelets (PLT) are measured in 10\^9/L. Neutrophils, lymphocytes, and Monocytes are reported as percentages (%). CRP is measured in mg/dL. The neutrophil-to-lymphocyte ratio (NLR) is reported as a unitless ratio.
Time frame: Baseline, 4 weeks after surgery, 12 weeks after surgery
Inflammation Markers 3: Procalcitonin, Blood Culture (BC), Serum Amyloid A (SAA), Zonulin, Cytokine (TNF-α, IFN-γ, IL-2, IL-6, IL-10, IL-12, IL-17)
Procalcitonin, BC, SAA, Zonulin, Cytokine (TNF-α, IFN-γ, IL-2, IL-6, IL-10, IL-12, IL-17) are assessed using venous blood samples. Procalcitonin is measured in ng/mL, SAA in mg/L, and Zonulin in ng/mL. BC is recorded as a qualitative result (Positive/Negative). Cytokines assessed include TNF-α, IFN-γ, IL-2, IL-6, IL-10, IL-12, and IL-17, measured in pg/mL.
Time frame: Baseline, 4 weeks after surgery, 12 weeks after surgery
Immune-related Markers 1: Natural Killer cell cytotoxicity (NK cytotoxicity), Natural Killer cell subset (NK subset)
Immune-related markers are assessed using venous blood samples. NK cytotoxicity and NK subset are reported as percentages (%).
Time frame: Baseline, 4 weeks after surgery, 12 weeks after surgery
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30)
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) is used to assess quality of life in patients with cancer. It consists of three domains: global health status/quality of life, functional, and symptom domains, with a total of 30 items. Scores are transformed to a scale ranging from 0 to 100 according to the EORTC QLQ-C30 scoring manual. Higher scores for global health status/quality of life and the functional domain indicate better quality of life, whereas higher scores for the symptom domain indicate worse quality of life.
Time frame: 1 week before surgery, 4 weeks after surgery, 12 weeks after surgery
Bowel Function Assessment 1: Bowel Diary
As part of the bowel function assessment, a bowel diary is used to record the frequency and form of bowel movements.
Time frame: 1 week before surgery, 4 weeks after surgery, 12 weeks after surgery
Bowel Function Assessment 2: Postoperative Bowel Function Questionnaire
As part of the bowel function assessment, the Postoperative Bowel Function Questionnaire is used to assess postoperative bowel function and recovery, including time to first passage of flatus, time to first bowel movement, and other related measures.
Time frame: 1 week before surgery, 4 weeks after surgery, 12 weeks after surgery
Nutritional Status Assessment 1: Patient-Generated Subjective Global Assessment (PG-SGA)
As part of the nutritional status assessment, the Patient-Generated Subjective Global Assessment (PG-SGA) is used to evaluate nutritional status based on factors including changes in body weight and dietary intake, gastrointestinal symptoms affecting food intake, physical examination findings, and comorbidities.
Time frame: 1 week before surgery, 4 weeks after surgery, 12 weeks after surgery
Nutritional Status Assessment 2: Prognostic Nutritional Index (PNI)
As part of the nutritional status assessment, the Prognostic Nutritional Index (PNI) is calculated based on Serum Albumin and Total Lymphocyte Count. PNI is calculated as 10 × Serum Albumin (g/dL) + 0.005 × Total Lymphocyte Count (/mm³).
Time frame: 1 week before surgery, 4 weeks after surgery, 12 weeks after surgery
Fecal Microbiome (16S/Shotgun, NGS, SCFA)
Fecal collection kits are sent to participants, who are instructed to collect stool samples at home within 2 days of each visit. The collected samples are placed in the designated kits and returned by courier to the analytical laboratory.
Time frame: 1 week before surgery, 4 weeks, 12 weeks after surgery
Tumor Transcriptome (RNA-seq)
Normal tissue and tumor tissue are collected during surgery.
Time frame: During surgery
Adaptive immunity test (T cell exhaustion marker, CEA/NY-ESO-1/ST4-specific T cell)
Adaptive immunity is assessed using T-cell exhaustion markers and CEA/NY-ESO-1/ST4-specific T-cell responses. These measurements are used to analyze the association between changes in immune status before and after surgery and clinical prognosis, and to evaluate changes in immune response following probiotic intake.
Time frame: Baseline, 4 weeks, 12 weeks after surgery
Started Aug 2026 (actual). Primary completion is estimated for Apr 2028, 20 months after the start.
Of 404 interventional studies with no phase under Colonic Neoplasms, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 51. This study's planned 20 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.